© 2024 MJH Life Sciences™ , Cannabis Science and Technology . All rights reserved.
Tilray’s Aphria RX obtained a cannabis trading license recently in Germany.
On July 29, 2024, Germany granted a cannabis trading license to Tilray’s Aphria RX GmbH (Aphria RX) (1). Through obtaining the cannabis trading license, Aphria RX will be able to distribute and sell a variety of medicinal cannabis products to medical wholesalers, pharmacies, and hospitals located in Germany. Tilray is well-known in the industry for their involvement in various sectors such as, cultivation, distribution, production, and medical cannabis research (1).
"This milestone of Aphria RX obtaining both its new cultivation license as well as its trading license further expands Tilray's leadership in medical cannabis research, cultivation, production and distribution in Germany and once again proves our commitment to be one of the most responsible, trusted and market leading cannabis companies in the world with a portfolio of innovative and high-quality products that address the needs of patients. We remain dedicated to advocating for responsible cannabis regulations, education and research and accessibility to high-quality medical cannabis," Denise Faltischek, Tilray’s Chief Strategy Officer and Head of International commented (1).
With the new cannabis trading license, Tilray will be able to expand in the cannabis market in Germany. According to the press release (1), “Tilray strongly believes that these developments will have a positive impact on the health and wellbeing of patients in Germany. Tilray is committed to working with the German government and all stakeholders to promote improved access to medical cannabis, optimize care for patients, and advance the science of cannabis.”
Germany legalized recreational cannabis on April 1, 2024 (2). As restrictions have loosened, the country will be under watch to see the effects this will cause for the cannabis industry.
References